

## ABBREVIATIONS

ACD	Australian Cancer Database
Act	<i>National Health Act 1953</i>
AIHW	Australian Institute of Health and Welfare
ALK	anaplastic lymphoma kinase
ALLG	Australasian Leukaemia and Lymphoma Group
AMWG	Access to Medicines Working Group
ANZCHOG	Australian New Zealand Children's Haematology/Oncology Group
ARTG	Australian Register of Therapeutic Goods
AusPAR	Australian Public Assessment Report
AYAs	adolescents and young adults
BCNA	Breast Cancer Network Australia
CADTH	Canadian Agency for Drug Technologies and Health
CAV	Cancer Action Victoria
CBCF	Cure Brain Cancer Foundation
CCA/COSA	Cancer Council Australia/Clinical Oncology Society of Australia
CDA	Cancer Drugs Alliance
CDF	Cancer Drugs Fund
CDR	Common Drug Review
CLL	Chronic Lymphocytic Leukaemia
committee	Senate Community Affairs Reference Committee
Council	United Kingdom Citizen's Council
CVA	Cancer Voices Australia
DAE	Deloitte Access Economics

DOH	Department of Health
EFC	Efficient Funding of Chemotherapy
EMA	European Medicines Agency
F1	Formulary 1 medicines
F2	Formulary 2 medicines
FDA	Food and Drug Administration
Guidelines	Pharmaceutical Benefits Advisory Committee Guidelines
HSANZ	Haematology Society of Australia and New Zealand
HTA	Health Technology Assessment
HSDP	Highly Specialised Drugs Program
IARC	International Agency for Research on Cancer
ICER	Incremental Cost Effectiveness Ratio
IPU	Individual Patient Use
Janssen	Janssen-Cilag Pty Ltd
LFA	Leukaemia Foundation of Australia
Lilly	Eli Lilly Australia
LSDP	Life Saving Drugs Programme
MA	Medicines Australia
MAP	Managed Access Programme
MBS	Medical Benefits Schedule
MES	Managed Entry Scheme
Minister	Minister for Health
MOGA	Medical Oncology Group of Australia
MSAC	Medical Services Advisory Committee
MSD	Merck Sharp and Dohme
NCR	national chemotherapy registry

NICE	National Institute for Health and Care Excellence
NHPA	National Health Priority Areas
NHS	National Health Service
NMP	National Medicines Policy
NN	Novo Nordisk
Novartis	Novartis Oncology Australia New Zealand
OCA	Ovarian Cancer Australia
OS	overall survival
Panel	Expert Panel, Review of Medicines and Medical Devices
PAG	Provincial Advisory Group
PATS	Patient Assisted Travel Schemes
PBAC	Pharmaceutical Benefits Advisory Committee
PBS	Pharmaceutical Benefits Scheme
pCODR	pan-Canadian Oncology Drug Review
PCPA	Private Cancer Physicians of Australia
pERC	pCODR Expert Review Committee
PFS	Progression Free Survival
Price Agreement	An agreement made under section 85AD of the <i>National Health Act 1953</i>
RCA	Rare Cancers Australia
SAS	Special Access Scheme
SHPA	Society of Hospital Pharmacists of Australia
SIBs	social impact bonds
TGA	Therapeutic Goods Administration
UK	United Kingdom
US	United States
WISH	World Innovation Summit for Health

WM	Waldenstrom's Macroglobulinemia
----	---------------------------------